Tenofovir plasma trough concentrations in people with HIV treated with doravirine versus other antiretroviral regimens. 2021

Dario Cattaneo, and Marta Fusi, and Valeria Micheli, and Chiara Resnati, and Paola Meraviglia, and Maria Vittoria Cossu, and Stefania Vimercati, and Giulia Carlotta Bisinella, and Sara Baldelli, and Spinello Antinori, and Cristina Gervasoni
Unit of Clinical Pharmacology.

UI MeSH Term Description Entries
D011728 Pyridones Pyridine derivatives with one or more keto groups on the ring. Pyridinones
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068698 Tenofovir An adenine analog REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone. (R)-9-(2-phosphonylmethoxypropyl)adenine,9-(2-Phosphonomethoxypropyl)adenine,9-(2-Phosphonylmethoxypropyl)adenine,9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer,9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098,9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer,9-PMPA (tenofovir),Tenofovir Disoproxil,Tenofovir Disoproxil Fumarate,Viread,Disoproxil Fumarate, Tenofovir,Disoproxil, Tenofovir,Fumarate, Tenofovir Disoproxil
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

Dario Cattaneo, and Marta Fusi, and Valeria Micheli, and Chiara Resnati, and Paola Meraviglia, and Maria Vittoria Cossu, and Stefania Vimercati, and Giulia Carlotta Bisinella, and Sara Baldelli, and Spinello Antinori, and Cristina Gervasoni
April 2023, Therapeutic drug monitoring,
Dario Cattaneo, and Marta Fusi, and Valeria Micheli, and Chiara Resnati, and Paola Meraviglia, and Maria Vittoria Cossu, and Stefania Vimercati, and Giulia Carlotta Bisinella, and Sara Baldelli, and Spinello Antinori, and Cristina Gervasoni
December 2024, HIV research & clinical practice,
Dario Cattaneo, and Marta Fusi, and Valeria Micheli, and Chiara Resnati, and Paola Meraviglia, and Maria Vittoria Cossu, and Stefania Vimercati, and Giulia Carlotta Bisinella, and Sara Baldelli, and Spinello Antinori, and Cristina Gervasoni
June 2023, The Journal of antimicrobial chemotherapy,
Dario Cattaneo, and Marta Fusi, and Valeria Micheli, and Chiara Resnati, and Paola Meraviglia, and Maria Vittoria Cossu, and Stefania Vimercati, and Giulia Carlotta Bisinella, and Sara Baldelli, and Spinello Antinori, and Cristina Gervasoni
September 2022, HIV medicine,
Dario Cattaneo, and Marta Fusi, and Valeria Micheli, and Chiara Resnati, and Paola Meraviglia, and Maria Vittoria Cossu, and Stefania Vimercati, and Giulia Carlotta Bisinella, and Sara Baldelli, and Spinello Antinori, and Cristina Gervasoni
January 2011, Antiviral therapy,
Dario Cattaneo, and Marta Fusi, and Valeria Micheli, and Chiara Resnati, and Paola Meraviglia, and Maria Vittoria Cossu, and Stefania Vimercati, and Giulia Carlotta Bisinella, and Sara Baldelli, and Spinello Antinori, and Cristina Gervasoni
May 2021, AIDS (London, England),
Dario Cattaneo, and Marta Fusi, and Valeria Micheli, and Chiara Resnati, and Paola Meraviglia, and Maria Vittoria Cossu, and Stefania Vimercati, and Giulia Carlotta Bisinella, and Sara Baldelli, and Spinello Antinori, and Cristina Gervasoni
January 2016, Journal of pharmaceutical health care and sciences,
Dario Cattaneo, and Marta Fusi, and Valeria Micheli, and Chiara Resnati, and Paola Meraviglia, and Maria Vittoria Cossu, and Stefania Vimercati, and Giulia Carlotta Bisinella, and Sara Baldelli, and Spinello Antinori, and Cristina Gervasoni
May 2023, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,
Dario Cattaneo, and Marta Fusi, and Valeria Micheli, and Chiara Resnati, and Paola Meraviglia, and Maria Vittoria Cossu, and Stefania Vimercati, and Giulia Carlotta Bisinella, and Sara Baldelli, and Spinello Antinori, and Cristina Gervasoni
October 2016, Medicine,
Dario Cattaneo, and Marta Fusi, and Valeria Micheli, and Chiara Resnati, and Paola Meraviglia, and Maria Vittoria Cossu, and Stefania Vimercati, and Giulia Carlotta Bisinella, and Sara Baldelli, and Spinello Antinori, and Cristina Gervasoni
May 2013, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!